A Registered Cohort Study on Neurodegenerative Associated With Disorders Sleep Disorder.

Study Overview
=================
Brief Summary
-----------------
Cognitive impairment often appears in neurodegenerative diseases, and it is expected to further study the mechanism of sleep disorders associated with the progression of neurodegenerative diseases by exploring the clinical manifestations, imaging, and biological marker changes of sleep disorders in neurodegenerative diseases.

Official Title
-----------------
A Registered Observational Cohort Study on Neurodegenerative Associated With Disorders Sleep

Conditions
-----------------
Neurodegenerative Disorder

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of neurodegenerative disease. patients experience insomnia, excessive drowsiness, or confusion at night. Patients experience frequent awakenings, daily sleep episodes, or nocturnal confusion. The presence of one or more of the following characteristics: a. wandering at night with inappropriate activity; b. agitation, combativeness; c. confusion, disorientation, or marked delirium. Polysomnographic monitoring showed the following two conditions: a. poor sleep efficiency, increased number and duration of awakenings; b. multiple sleep latency tests showed increased daytime sleepiness. Presence of other medical symptoms that do not indicate the primary disease. Other sleep disorders (e.g., periodic limb movement disorders, obstructive sleep apnea syndrome) may be present, but do not explain the patient 's main symptoms. any of the above can be diagnosed Exclusion Criteria: Patients with other neurological disorders. Pregnant or lactating women.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurodegenerative disorders associated with sleep disorders<br> | Other: Data collection<br>* Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PSQI Scores | Pittsburgh Sleep Quality Index (PSQI), | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MoCA scores | The Montreal Cognitive Assessment (MoCA) | Baseline | 
| ACE-III scores | Addenbrooke's Cognitive Examination (ACE) score | Baseline | 
| HRV (ms) | Heart rate variability (HRV) was calculated as the maximum bpm - minimum bpm. | Baseline | 
| Plasma Aβ-42 levels (ng/ml) |  | Baseline | 
| Vic | The intra-cellular compartment (Vic) of the Neurite Orientation Dispersion and Density Imaging (NODDI) model represents diffusion within the axons and cells. | Baseline | 
| PAF (Hz) | The alpha-peak frequency (PAF) is the frequency with the highest power within the alpha-band. | Baseline | 
| Vic | The intra-cellular compartment (Vic) of the Neurite Orientation Dispersion and Density Imaging (NODDI) model represents diffusion within the axons and cells. | 1 year after baseline |